I'm LongbridgeAI, I can summarize articles.ImmunityBio held its 2026 Annual Meeting, where shareholders re-elected nine directors, including Executive Chairman Patrick Soon-Shiong, and ratified Deloitte & Touche LLP as the independent auditor. The meeting saw strong engagement with approximately 85% of shares represented. While analysts maintain a 'Buy' rating with a $15 target, TipRanks' AI tool rates the stock as 'Neutral' due to weak financials and bearish technicals.
ImmunityBio ( (IBRX) ) has issued an announcement.
On June 9, 2026, ImmunityBio, Inc. held its 2026 Annual Meeting of Stockholders, with approximately 85% of outstanding common shares represented, establishing a quorum and signaling strong shareholder engagement. At the meeting, stockholders re-elected nine directors, including Executive Chairman Patrick Soon-Shiong, M.D., to one-year terms expiring at the 2027 annual meeting, reinforcing continuity in the company’s leadership and governance structure.
Stockholders also ratified the appointment of Deloitte & Touche LLP as ImmunityBio’s independent registered public accounting firm for the fiscal year ending December 31, 2026. This ratification supports ongoing financial reporting oversight and may bolster investor confidence in the company’s accounting practices and regulatory compliance as it advances its biopharmaceutical programs.
The most recent analyst rating on (IBRX) stock is a Buy
with a $15.00 price target.
To see the full list of analyst forecasts on ImmunityBio stock,
see the IBRX Stock Forecast page.
Spark’s Take on IBRX Stock
According to Spark, TipRanks’ AI Analyst, IBRX is a Neutral.
The score is held down primarily by weak financials (large losses, heavy cash burn, and negative equity) and bearish near-term technicals (negative MACD, sub-50 RSI, and price below key moving averages). Corporate events provide some support via improved financing and strategic BCG supply positioning, but valuation is constrained by negative earnings and no dividend information.
To see Spark’s full report on IBRX stock,
click here.
More about ImmunityBio
ImmunityBio, Inc. is a biotechnology company focused on developing immunotherapies, including cell-based and antibody treatments, aimed at harnessing the immune system to treat cancers and infectious diseases. The company targets patients with difficult-to-treat conditions and operates in the highly regulated U.S. biopharmaceutical market, where governance and investor confidence are critical to its strategy.
Average Trading Volume: 17,318,115
Technical Sentiment Signal: Buy
Current Market Cap: $7.59B